View in EDS HTML Full Text PDF Full Text

CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.

Saved in:
Bibliographic Details
Title: CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.
Authors: Funnell T; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 2B5., Tasaki S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Oloumi A; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 2B5.; Janssen Pharmaceuticals, Toronto, Ontario, Canada., Araki S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Kong E; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 2B5., Yap D; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 2B5., Nakayama Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Hughes CS; Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3., Cheng SG; Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3., Tozaki H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Iwatani M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Sasaki S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Ohashi T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Miyazaki T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Morishita N; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Morishita D; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Ogasawara-Shimizu M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Ohori M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Nakao S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Karashima M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Sano M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Murai A; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Nomura T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Uchiyama N; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Kawamoto T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Hara R; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.; Fujirebio Inc., Tokyo, Japan., Nakanishi O; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.; Department of Innovative Drug Discovery and Development, Japan Agency for Medical Research and Development, Osaka, Japan., Shumansky K; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 2B5., Rosner J; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 2B5.; Advanced Research Computing, University of British Columbia, Vancouver, British Columbia, Canada., Wan A; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 2B5., McKinney S; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 2B5., Morin GB; Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3.; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada, V6H 3N1., Nakanishi A; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan., Shah S; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 2B5., Toyoshiba H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan. hiroyoshi.toyoshiba@takeda.com., Aparicio S; Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 1L3. saparicio@bccrc.ca.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 2B5. saparicio@bccrc.ca.
Source: Nature communications [Nat Commun] 2017 Feb 23; Vol. 8 (1), pp. 7. Date of Electronic Publication: 2017 Feb 23.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2041-1723
DOI:10.1038/s41467-016-0008-7